Senior Director, Clinical Development, Research and Development, HematologyCSL Behring, King of Prussia, PA, USAKing of Prussia, Pennsylvania, United States
OC 52.1 - Assessing the safety profile of AMT-060 and etranacogene dezaparvovec gene therapies across clinical trials in people with severe/moderately severe hemophilia B
Tuesday, June 27, 202310:45 – 11:00 ET
OC 52.5 - Phase 3 HOPE-B trial of etranacogene dezaparvovec in severe/moderately severe hemophilia B: A post hoc responder analysis of participants who received full dose and responded to treatment
Tuesday, June 27, 202311:45 – 12:00 ET
